We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Recordati SpA (REC) EUR0.125

Sell:€52.28 Buy:€52.34 Change: €0.64 (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.64 (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.64 (1.24%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.

Contact details

Via Matteo Civitali, 1
+39 (02) 487871

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€10.81 billion
Shares in issue:
205.53 million
Milan Stock Exchange
Euronext 100

Key personnel

  • Robert Koremans
    Chief Executive Officer, Executive Director
  • Luigi Corte
    Chief Financial Officer, Executive Director
  • Gabriele Finzi
    Executive Vice President - Corporate Development and Licensing
  • Alberto Martinez
    Executive Vice President - Specialty and Primary Care Business Unit
  • Scott Pescatore
    Executive Vice President - Rare Disease Business Unit
  • Roberto Teruzzi
    Executive Vice President - Group Industrial Operations
  • Milan Zdravkovic
    Executive Vice President - Research and Development
  • Giuseppe Gualazzini
    Senior Vice President - Group Human Resources
  • Erdem Cinar
    Vice President, South East Region, General Manager, Recordati Ilac, Specialty & Primary Care
  • Massimo Grandi
    Vice President, Southern Europe Region, General Manager, Pharmaceuticals Italy, Specialty & Primary Care

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.